Ukuqonda i-ACR20 (i-American College of Rheumatology) Imigaqo

Iigama zeSigqeba seNtsholongwane

Kwiimvavanyo zeklinikhi zonyango lwesifo se-rheumatoid, iimpawu eziqhelekileyo zisetyenziselwa ukuthelekisa ukuphumelela kwamachiza e-arthritis okanye unyango lwe-arthritis, okanye ukuthelekisa esinye isilingo kwenye. Imigaqo-nkqubo, eyaziwa njenge-American College College yeRheumatology (ACR), imilinganiselo esetyenziswe phantse zonke iiphando ezipapashiweyo ezijonge ukuphumelela (ukuphumelela) zonyango kuzo zonke iintlobo zesifo se- rheumatic .

I-ACR20 yayisisethi sokuqala seenkqubo ezimiselweyo, zilandelwa kamva yi-ACR50 kunye ne-ACR70.

Ukusetyenziswa kwe-ACR Criteria

Imilinganiselo ye-ACR isetyenziselwa ukuvavanya nokuseka ukuphuculwa kwithenda okanye izibalo ezidibeneyo kunye nokuphuculwa kwezi zintathu zilandelayo:

Imilinganiselo ye-ACR ingasetyenziselwa ukunceda oogqirha ukuba baqinisekise ngokucacileyo ukuba unyango lwakho lusebenza ekuphuculeni iimpawu zakho ze-rheumatoid arthritis, nangona zihlala zisetyenziselwa ukuhlolwa kweeklinikhi.

Ukuqonda ukuba yiyiphi i-ACR20, i-ACR50, ne-ACR70 ichaza kwiiNtsholongwane zeZliniki

Iimvavanyo zonyango zibika ipesenteji yabathathi-nxaxheba abaye bafumana i-ACR20, i-ACR50 kunye ne-ACR70. Ngokomzekelo, ukuba uphando lubhengeze ukuba ama-55 eepesenti zezigulane ziphumelele kwi-ACR20, oko kuthetha ukuba iipesenti ezingama-55 zezigulane kwisifundo siphumelele ukuphuculwa kweepesenti ezingama-20 kwithenda okanye izibalo ezidibeneyo, kunye nokuphuculwa kweepesenti ezingama-20 kwizinto ezintathu ezilandelayo.

Ukuba uvavanyo lwekliniki lubonisa ukuba ama-40 eepesenti zezigulane ziphumelele kwi-ACR50, oko kuthetha ukuba iipesenti ezingama-40 zezigulane kwisifundo siphumelele ukuphuculwa kwepesenti ezingama-50 kwithenda okanye izibalo ezidibeneyo, kunye nokuphuculwa kweepesenti ezingama-50 kwizinto ezintathu ezithintekayo. Kuyafana nakwi-ACR70, kuphela ngezinga lokuphucula iipesenti ezingama-70. Ukuze izigulane zihlolwe ngokusebenzisa iimfuno ze-ACR, kufuneka zigqityile ityala leklinikhi.

I-ACR20 Ngaba i-FDA ivunywe

Ulawulo lwe-US Food and Drug Administration (FDA) lincoma ukusebenzisa i-ACR20 njengesilinganiselo sesiphumo sokhetho lwezilwanyana zamachiza ezisetyenziselwa ukunyanga i-rheumatoid arthritis. Oku kuvunywa kukhokelela ekusebenziseni okusasazeka kwe-ACR20 kwizilingo zeclini. Ngokuqhelekileyo kuthethwa nje ngokuba yi-ACR20 kuba ifuna ubuncinci ukuphucula iipesenti ezingama-20 kwimiqathango engentla.

Imithombo:

> Felson DT, Anderson JJ, uBoers M, et al. Ikholeji yaseRamerican yeRheumatology Inkcazo yokuQala Inkcazo yokuPhucula kwiRumatoid Arthritis. Arthritis & Rheumatism. 1995; 38: 727-735. i-doi: 10.1002 / ubugcisa.1780380602.

> Felson DT, MP. I-ACR20 kunye nokuchaza iNdawo yokuLondoloza ukuphendula kwiiRheumatic Diseases: Kuninzi Kwinto Enhle. Uphando lwe-arthritis kunye neyeza . 2014; 16 (1): 101. i-doi: 10.1186 / ar4428.

Johns Hopkins Isikhungo seArthritis. Izikhokelo zoLwazi lwe-ACR: I-ACR Inkcazo yokuPhucula kwiimvavanyo ze-RA. Johns Hopkins Medicine. Ukuhlaziywa kwe-Agasti 16, 2017.

I-Rocha K. I-ACR Score: Ukulinganisa i-Rheumatoid Arthritis. I-Rheumatoid Arthritis Support Network. Ukuhlaziywa kwe-Matshi 22, 2017.